ISRCTN21335128已完成未知
Italian Sarcoma Group: non-metastatic OsteoSarcoma 1
Orthopaedic Institute Rizzoli (Istituti Ortopedici Rizzoli) (Italy)0 个研究点目标入组 246 人开始时间: 2006年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 246
研究概览
简要总结
2012 Results article in https://pubmed.ncbi.nlm.nih.gov/22564997/ (added 01/09/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with typical radiographic and histological features of primary, high-grade central osteosarcoma
- •2. Tumour located in the extremity
- •3. No previous history of cancer and no prior treatments
- •4. Aged under 40
- •5. No co-existing disease contraindicating chemotherapy
- •6. No evidence of metastases at diagnosis
- •7. Informed consent
排除标准
- •1. Metastatic osteosarcoma
- •2. Previous history of cancer
- •3. Co-existing disease contraindicating chemotherapy
- •4. No informed consent
研究者
相似试验
已完成
2 期
Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable OsteosarcomaMetastatic OsteosarcomaRelapsed OsteosarcomaNCT01804374Italian Sarcoma Group38
招募中
2 期
A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in OsteosarcomaOsteosarcomaNCT05926492Second Affiliated Hospital, School of Medicine, Zhejiang University160
尚未招募
2 期
Investigate the effect of Propranolol and Celecoxib combine with Receptor activator of nuclear factor kappa-Ã?â?? ligand (RANKL) blockade therapy during the perioperative period of Osteosarcoma (Bone cancer) patients.CTRI/2022/10/046252Tata Memorial Hospital
已完成
2 期
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasEwing SarcomasChondrosarcomasOsteosarcomasChondromaCIC-Rearranged SarcomaNCT02389244UNICANCER163
已完成
不适用
A European treatment protocol for bonesarcomain patients older than 40 years (EURO-B.O.S.S.)C40Malignant neoplasm of bone and articular cartilage of limbsDRKS00000942Klinikum Stuttgart135